Great thoughts there my man. ECQ is a vehicle to monetise otherwise private warf technology. It would not be listing as Cynata therapeutics and taking up board positions if this wasn't a highly promising prospect.
It will take time but as you mention Jatter ISN - all good things take time. If this can gain a partner through to the trials next year be worth a lot more than we are now.
I am holding the options for leveridge into 2014.
Samwise I once was in cgp but missed the recent rise. I am waiting for ecq now.
ECQ Price at posting:
2.3¢ Sentiment: Buy Disclosure: Held
